558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Sumanta Pal; Ben Tran; John Haanen; Michael Hurwitz; Adrian Sacher; Neeraj Agarwal; Nizar Tannir; Elizabeth Budde; Simon Harrison; Sebastian Klobuch; Sagar Patel; Mary Lee Dequeant; Verena Karsten; Kaitlyn Cohen; Ellen Gurary; Henia Dar; Anna Ma; Anjali Sharma; Samer Srour

doi:10.1136/jitc-2022-SITC2022.0558

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Free

Authors

Sumanta Pal City of Hope Comprehensive Cancer Center, Duarte, CA, United States PubMed articles Google scholar articles
Ben Tran Peter MacCallum Cancer Centre, Melbourne, Australia PubMed articles Google scholar articles
John Haanen Netherlands Cancer Institute, Amsterdam, Netherlands PubMed articles Google scholar articles
Michael Hurwitz Yale School of Medicine, New Haven, CT, United States PubMed articles Google scholar articles
Adrian Sacher Princess Margaret Cancer Centre, Toronto, Canada PubMed articles Google scholar articles
Neeraj Agarwal University of Utah, Salt Lake City, UT, United States PubMed articles Google scholar articles
Nizar Tannir The University of Texas, Houston, TX, United States PubMed articles Google scholar articles
Elizabeth Budde City of Hope Comprehensive Cancer Center, Duarte, CA, United States PubMed articles Google scholar articles
Simon Harrison Peter MacCallum Cancer Centre, Melbourne, Australia PubMed articles Google scholar articles
Sebastian Klobuch Netherlands Cancer Institute, Amsterdam, Netherlands PubMed articles Google scholar articles
Sagar Patel University of Utah, Salt Lake City, UT, United States PubMed articles Google scholar articles
Mary Lee Dequeant CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Verena Karsten Formerly CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Kaitlyn Cohen CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Ellen Gurary CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Henia Dar CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Anna Ma CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Anjali Sharma CRISPR Therapeutics, Boston, MA, United States PubMed articles Google scholar articles
Samer Srour The University of Texas, Houston, TX, United States PubMed articles Google scholar articles

Citation

Pal S, Tran B, Haanen J, et al

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0558

Publication history

First published November 7, 2022.

Online issue publication

November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password